You can seek FDA approval to launch a generic drug before the expiration of BIKTARVY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BIKTARVY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BIKTARVY:-

You can seek FDA approval to launch a generic drug before the expiration of CLENPIQ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CLENPIQ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CLENPIQ:-

You can seek FDA approval to launch a generic drug before the expiration of EMROSI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EMROSI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EMROSI:-

You can seek FDA approval to launch a generic drug before the expiration of GALAFOLD's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the GALAFOLD's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on GALAFOLD:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of LIVMARLI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LIVMARLI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LIVMARLI:-

You can seek FDA approval to launch a generic drug before the expiration of LOTEMAX SM's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LOTEMAX SM's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LOTEMAX SM:-

You can seek FDA approval to launch a generic drug before the expiration of NEXTERONE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NEXTERONE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NEXTERONE:-

You can seek FDA approval to launch a generic drug before the expiration of OPZELURA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the OPZELURA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on OPZELURA:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of ORLADEYO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ORLADEYO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ORLADEYO:-

You can seek FDA approval to launch a generic drug before the expiration of OTEZLA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the OTEZLA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on OTEZLA:-

You can seek FDA approval to launch a generic drug before the expiration of RADICAVA ORS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the RADICAVA ORS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on RADICAVA ORS:-

You can seek FDA approval to launch a generic drug before the expiration of RINVOQ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the RINVOQ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on RINVOQ:-

You can seek FDA approval to launch a generic drug before the expiration of RYBELSUS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the RYBELSUS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on RYBELSUS:-

You can seek FDA approval to launch a generic drug before the expiration of RYZUMVI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the RYZUMVI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on RYZUMVI:-

You can seek FDA approval to launch a generic drug before the expiration of SUFLAVE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SUFLAVE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SUFLAVE:-

You can seek FDA approval to launch a generic drug before the expiration of TYRVAYA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TYRVAYA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TYRVAYA:-

You can seek FDA approval to launch a generic drug before the expiration of VALTOCO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VALTOCO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VALTOCO:-

You can seek FDA approval to launch a generic drug before the expiration of XYWAV's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the XYWAV's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on XYWAV:-